BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study
February 01, 2019 10:53 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced the publication of a paper in Clinical Infectious Disease—a journal of the Infectious Disease Society of...
Fedora Pharmaceuticals and Meiji Seika Pharma Sign Basic Agreement to Establish NacuGen Therapeutics Inc., a Joint Venture to Develop and Commercialize Nacubactam for Bacterial Infections
January 07, 2019 09:00 ET
|
Nacugen Therapeutics, Inc.
EDMONTON, Alberta and Tokyo , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. (headquarters: Edmonton, Alberta, Canada; Chief Executive Officer: Christopher G. Micetich, hereinafter...
New Genomic Technology Advances Fight Against Global Health Threat of Antibiotic Resistance
December 06, 2018 09:14 ET
|
Phase Genomics
SEATTLE, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Phase Genomics, the leader in proximity-ligation genome assembly technology released an antimicrobial resistance (AMR) study led by researchers from the...
BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round
September 18, 2018 08:52 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 18, 2018 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has begun patient enrollment in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...
HP Delivers Innovations to Public Health with New CDC Pilot Program
August 27, 2018 11:01 ET
|
HP Inc.
News highlights CDC launches HP pilot program with the purchase of HP BioPrinters for four regional labs in New York, Minnesota, Tennessee, and Wisconsin.HP BioPrinters, with inkjet printing...
Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
June 11, 2018 07:00 ET
|
Summit Therapeutics plc
Highlights the Power of the Discuva Platform to Identify Novel Antibiotic Targets OXFORD, United Kingdom and CAMBRIDGE, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...
Avivagen Reports Positive Proof of Concept in Preventing C. Difficile Infection
April 10, 2017 07:42 ET
|
Avivagen Inc.
OTTAWA, April 10, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a company with a proven and commercially-ready, patent-protected product...
Fedora Pharmaceuticals Receives Support from the Government of Canada to Battle Antimicrobial Resistance with Novel Pipeline of Antibiotic Candidates
January 16, 2017 10:51 ET
|
Fedora Pharmaceuticals, Inc.
EDMONTON, Alberta , Jan. 16, 2017 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. announced they have received non-refundable financial contribution from the National Research Council of Canada’s...